Celldex Therapeutics Price to Free Cash Flow Ratio 2010-2022 | CLDX
Historical price to free cash flow ratio values for Celldex Therapeutics (CLDX) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Celldex Therapeutics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-03-24 |
36.56 |
|
0.00 |
| 2022-12-31 |
44.57 |
$-2.25 |
0.00 |
| 2022-09-30 |
28.11 |
$-2.19 |
0.00 |
| 2022-06-30 |
26.96 |
$-1.70 |
0.00 |
| 2022-03-31 |
34.06 |
$-1.52 |
0.00 |
| 2021-12-31 |
38.64 |
$-1.45 |
0.00 |
| 2021-09-30 |
53.99 |
$-1.52 |
0.00 |
| 2021-06-30 |
33.44 |
$-1.08 |
0.00 |
| 2021-03-31 |
20.60 |
$-1.17 |
0.00 |
| 2020-12-31 |
17.52 |
$-1.41 |
0.00 |
| 2020-09-30 |
14.83 |
$-1.82 |
0.00 |
| 2020-06-30 |
13.00 |
$-2.58 |
0.00 |
| 2020-03-31 |
1.66 |
$-2.87 |
0.00 |
| 2019-12-31 |
2.23 |
$-3.25 |
0.00 |
| 2019-09-30 |
2.13 |
$-4.10 |
0.00 |
| 2019-06-30 |
2.68 |
$-4.34 |
0.00 |
| 2019-03-31 |
4.92 |
$-5.32 |
0.00 |
| 2018-12-31 |
2.97 |
$-7.25 |
0.00 |
| 2018-09-30 |
6.77 |
$-7.89 |
0.00 |
| 2018-06-30 |
7.55 |
$-9.68 |
0.00 |
| 2018-03-31 |
34.95 |
$-10.53 |
0.00 |
| 2017-12-31 |
42.60 |
$-11.87 |
0.00 |
| 2017-09-30 |
42.90 |
$-12.47 |
0.00 |
| 2017-06-30 |
37.05 |
$-13.35 |
0.00 |
| 2017-03-31 |
54.15 |
$-16.08 |
0.00 |
| 2016-12-31 |
53.10 |
$-17.11 |
0.00 |
| 2016-09-30 |
60.60 |
$-16.52 |
0.00 |
| 2016-06-30 |
65.85 |
$-17.45 |
0.00 |
| 2016-03-31 |
56.70 |
$-15.87 |
0.00 |
| 2015-12-31 |
235.20 |
$-16.03 |
0.00 |
| 2015-09-30 |
158.10 |
$-17.38 |
0.00 |
| 2015-06-30 |
378.30 |
$-17.53 |
0.00 |
| 2015-03-31 |
418.05 |
$-17.50 |
0.00 |
| 2014-12-31 |
273.75 |
$-17.35 |
0.00 |
| 2014-09-30 |
194.40 |
$-17.00 |
0.00 |
| 2014-06-30 |
244.80 |
$-15.84 |
0.00 |
| 2014-03-31 |
265.05 |
$-15.38 |
0.00 |
| 2013-12-31 |
363.15 |
$-13.51 |
0.00 |
| 2013-09-30 |
531.45 |
$-13.87 |
0.00 |
| 2013-06-30 |
234.15 |
$-13.15 |
0.00 |
| 2013-03-31 |
173.70 |
$-12.41 |
0.00 |
| 2012-12-31 |
100.65 |
$-12.95 |
0.00 |
| 2012-09-30 |
94.50 |
$-13.84 |
0.00 |
| 2012-06-30 |
77.63 |
$-12.82 |
0.00 |
| 2012-03-31 |
76.35 |
$-13.55 |
0.00 |
| 2011-12-31 |
39.00 |
$-13.70 |
0.00 |
| 2011-09-30 |
34.28 |
$-12.09 |
0.00 |
| 2011-06-30 |
53.25 |
$-14.26 |
0.00 |
| 2011-03-31 |
60.30 |
$-15.99 |
0.00 |
| 2010-12-31 |
61.80 |
$-15.24 |
0.00 |
| 2010-09-30 |
60.00 |
$-16.97 |
0.00 |
| 2010-06-30 |
68.40 |
$-18.40 |
0.00 |
| 2010-03-31 |
92.10 |
$-21.22 |
0.00 |
| 2009-12-31 |
70.05 |
$-22.35 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.714B |
$0.002B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
